US FDA Approves BLA for Pfizer’s Respiratory Syncytial Virus Maternal Vaccine Candidate
Pfizer Inc. announced that the US Food and Drug Organization (FDA) has approved a Biologics License Application (BLA) for its respiratory syncytial infection (RSV) antibody candidate, PF-06928316 or RSVpreF, to treat Mama LRTI and serious Mama LRTI brought in newborn children from birth as long as a half year old enough by dynamic vaccination of […]
Continue Reading